Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

Rodman & Renshaw starts Zentalis at buy; PT $11

Rodman & Renshaw initiated coverage of Zentalis Pharmaceuticals (NASDAQ: ZNTL) with a “buy” rating and price target of $11.00. The stock closed at $4.50 on July 22. Zentalis is a clinical oncology innovator...

July 23, 2026

Markets

Clear Street starts Equillium at buy; PT $9

Clear Street initiated coverage of Equillium (NASDAQ: EQ) with a “buy” rating and price target of $9.00. The stock closed at $2.47 on July 20. Equillium is a clinical-stage biotechnology company developing therapies...

July 21, 2026

Markets

BTIG starts coverage of two TMS companies at buy, sees anticipated psilocybin therapy approval as potential catalyst for both

BTIG initiated coverage on two companies with “buy” ratings that it believes are undervalued players in the transcranial magnetic stimulation (TMS) space. Analyst Sam Eiber assigns target prices of $5 to Neuronetics...

July 20, 2026

Markets

Brookline starts Perimeter at buy; PT C$1.54

Brookline Capital Markets initiated coverage of Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) with a “buy” rating and price target of C$1.54 (US$1.11). The stock closed at C$0.32 on July 13. In March 2026...

July 14, 2026

Markets

WB starts Zura Bio at OP; sum-of-the-parts NPV estimate $13.90

William Blair launched coverage of Zura Bio (NASDAQ:ZURA) with an “outperform” rating and sum-of-the-parts NPV estimate of $13.90. The stock closed at $5.08 on July 7. Zura is a clinical-stage, multi-asset immunology...

July 8, 2026

Markets

Rodman & Renshaw starts Atossa at buy; PT $12

Rodman & Renshaw initiated coverage of Atossa Therapeutics (NASDAQ: ATOS) with a “buy” rating and price target of $12.00. The stock closed at $2.28 on July 6. Atossa, a clinical-stage biopharmaceutical company...

July 7, 2026

Markets

Paradigm Capital names Perimeter and maintains Profound as healthcare Top Picks

Paradigm Capital has named Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) as a new Top Pick with a “speculative buy” rating and C$0.95 price target. The stock closed at C$0.275 on July 3. Commenting on the FDA’s...

July 6, 2026

Markets

E.F. Hutton appoints healthcare investment banking veteran Bryan Kobel as managing director

Global investment bank E.F. Hutton & Co. has announced the appointment of former public company CEO Bryan Kobel as managing director. Mr. Kobel rejoins E.F. Hutton, where he previously served as managing director...

June 15, 2026

Markets

Rodman & Renshaw starts Kyntra Bio at buy; PT $30

Rodman & Renshaw initiated coverage of Kyntra Bio (NASDAQ: KYNB) with a “buy” rating and price target of $30.00. The stock closed at $6.63 on June 8. Kyntra Bio (formerly known as FibroGen) is a biopharmaceutical...

June 10, 2026

Markets

Clear Street starts LB Pharmaceuticals at buy; PT $45

Clear Street initiated coverage of LB Pharmaceuticals (NASDAQ: LBRX) with a “buy” rating and price target of $45.00. The stock closed at $28.33 on May 26th. LB Pharmaceuticals is a late-stage biopharmaceutical company...

May 26, 2026

Markets

Tivic rebrands as Valion Bio and changes ticker, closes down 28%

After changing its name from Tivic Health Systems (NASDAQ: TIVC) to Valion Bio (NASDAQ: VBIO), effective at market open today, the company’s stock price declined 28% to close at $1.01, after trading as low as $0.865...

April 28, 2026

Markets

Stifel starts Immunic at buy; PT $2.50

Stifel initiated coverage of Immunic (NASDAQ: IMUX) with a “buy” rating and price target of $2.50. The stock closed at $1.11 on April 15. Immunic is a biotechnology company developing vidofludimus calcium (VidoCa) for...

April 16, 2026

Markets

Rodman & Renshaw starts TuHURA at buy; PT $7

Rodman & Renshaw initiated coverage of TuHURA Biosciences (NASDAQ:HURA) with a “buy” rating and price target of $7.00. The stock closed at $3.15 on April 14th. TuHURA is currently undertaking a Phase 3 trial for its...

April 15, 2026

Markets

Piper starts Adagio at overweight; PT $3

Piper Sandler initiated coverage of Adagio Medical Holdings (NASDAQ: ADGM) with an “overweight” rating and price target of $3.00. The stock closed at $1.33 on April 13th. Adagio is a pre-commercial medtech company that...

April 14, 2026

Markets

Stifel starts Tectonic Therapeutic at buy; PT $75

Stifel initiated coverage of Tectonic Therapeutic (NASDAQ:TECX) with a “buy” rating and price target of $75.00. The stock closed at $29.96 on April 13. Tectonic is a clinical-stage biotech, developing therapies...

April 13, 2026

Markets

Clear Street upgrades Korro Bio to buy; PT to $18.00 from $10.00

Clear Street upgraded Korro Bio (NASDAQ: KRRO) to “buy” from “hold” and raised its price target to $18.00 from $10.00, following Korro’s late January Analyst Day detailing their new lead program, KRRO-121 for...

February 18, 2026

Markets

Lake Street sees CMS’s proposed 2026 TULSA reimbursement as favorable

Lake Street Capital Markets senior research analyst, Ben Haynor, issued a research note today on Profound Medical (NASDAQ:PROF; TSX:PRN), reiterating his ‘buy’ rating and $11 target price on the company’s stock...

July 16, 2025

Markets

Light AI goes public on CBOE Canada, stock rallies on first day of trading

Light AI (CBOE CA: ALGO) announced the completion of its IPO (including the agents’ full exercise of their over-allotment option) and began trading on CBOE Canada today. Including the units sold pursuant to the over...

January 8, 2025

Markets

Lake Street analyst pitches Profound Medical as one of his ‘best ideas’ for 2025

Lake Street Capital Markets senior research analyst, Ben Haynor, issued a research note today on Profound Medical (NASDAQ:PROF; TSX:PRN), reiterating his ‘buy’ rating and $17 target price on the company’s stock...

January 2, 2025

Markets

Clear Street initiates coverage of several healthcare stocks

Analysts Kaveri Pohlman, PhD and Bill Maughan, PhD from Clear Street, a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, have launched coverage of several healthcare names. “The...

December 11, 2024

Markets

Leede Financial starts Nanalysis Scientific at buy; PT C$0.90

Leede Financial launched coverage of Nanalysis Scientific (TSXV: NSCI) (OTCQX: NSCIF) with a “speculative buy” rating and C$0.90 target price. The stock closed at $0.365 on November 22. Nanalysis operates two distinct...

November 25, 2024

Markets

Capricor prices common stock offering

Capricor Therapeutics (NASDAQ:CAPR) has priced a public offering of 4,412,000 common shares at a price of $17.00 per share. Capricor also granted underwriters a 30-day option to purchase up to an additional 661,800...

October 17, 2024

Subscribe